Primary Immunodeficiency (PIDD) Treatment & Management

Because PIDD symptoms resemble common illnesses, proper diagnosis requires:

• Blood work measuring antibody levels
• Genetic tests identifying specific mutations
• Family medical history review
• Special tests assessing how well your immune cells work

The most common types of Primary immunodeficiency diseases are:

Common Variable Immune Deficiency (CVID)
CVID is one of the most frequent primary immunodeficiency disorders, typically diagnosed in young adults. People with CVID have low levels of protective antibodies, making them vulnerable to recurring infections, particularly in the sinuses, lungs, and digestive tract. Many patients also experience fatigue and may develop autoimmune conditions.

X-linked Agammaglobulinemia (XLA)
XLA primarily affects males since it’s linked to the X chromosome. This condition is usually diagnosed in early childhood when maternal antibodies naturally decline. Patients with XLA cannot produce antibodies called immunoglobulins, leaving them highly susceptible to bacterial infections. Regular immunoglobulin replacement therapy is essential for these patients.

Severe Combined Immunodeficiency (SCID)
Often called “bubble boy disease,” SCID is a serious condition that appears in infancy. Babies with SCID lack the crucial immune cells necessary to fight infections, making common illnesses potentially life-threatening. Early diagnosis through newborn screening is critical, as bone marrow transplantation can be life-saving if performed in the first months of life.

Selective IgA Deficiency
This is the most common primary immunodeficiency, where patients lack or have very low levels of an antibody called Immunoglobulin A (IgA). While some people with selective IgA deficiency have no symptoms, others may experience frequent infections of the respiratory and digestive tracts. Many patients can lead normal lives with proper medical management.

The treatment can be given in two ways:

Intravenously (IVIG) – directly into a vein at an infusion center or at home. IG is given intravenously (IVIG) through an IV that can be used long-term.

Subcutaneously (SCIG) – under the skin, typically self-administered at home. This is between the skin and the muscle.

Both methods use unique pumps that ensure the right amount is delivered.

Most patients notice improvements within 3-6 months after starting immunoglobulin replacement therapy.

Here’s what to expect:

• First few weeks: You might feel worse temporarily as your body adjusts to the treatment
• 1-3 months: Many patients report fewer infections and less severe symptoms
• 3-6 months: Most patients experience a significant reduction in infection frequency
• 6-12 months: Your body typically reaches a stable state with optimal protection
• Ongoing maintenance: Regular treatments maintain protection long-term

Individual response varies depending on your specific PIDD type, the severity of your condition, and how well you maintain your treatment schedule.

Most insurance plans, including Medicare and Medicaid, cover immunoglobulin therapy and other primary immunodeficiency treatments. Our team works directly with insurance providers to maximize your benefits and minimize out-of-pocket expenses.